Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Injection
Active Ingredients: Glycopyrronium bromide 0.5mg/mL
Neostigmine metilsulfate 2.5mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Max Health Limited
Manufacturer: Martindale Pharmaceuticals, Essex, United Kingdom
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 11th day of July 2013.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).